AML – Revolution oder Evolution?
From Hämatologie Shortcasts by Dr. med. Richard Schabath, Dr. med. Andreas Hausmann, Dr. med. Stephan Fuhrmann
February 27, 2026 · 26 min · Season 5 · Episode 2
About this episode
The episode discusses the latest developments in AML therapy, focusing on the PARADIGM study and modern treatment strategies.
People in this episode
Host: Dr. Richard Schabath
Guest: Prof. Dr. Lars Bullinger
Topics covered
- AML therapy
- PARADIGM study
- chemotherapy
- triplet strategies
- clinical trials
- hematology
Keywords
- AML
- Azacitidin
- Venetoclax
- chemotherapy
- FLT3 inhibitors
- clinical trials
- hematology
Mentioned in this episode
Organizations: Charité – Universitätsmedizin Berlin
Products: Azacitidin, Venetoclax, FLT3-Inhibitoren, Gilteritinib, IDH1/2-Inhibitoren, Ivosidenib, Enasidenib, MENIN-Inhibitoren, Revumenib, Ziftomenib
More episodes of Hämatologie Shortcasts
- Zwischen ASH und ASCO: Praxisrelevante Updates aus Lymphom, AML und Myelofibrose · June 11, 2026 · 18 min
- ASH 2025 - Aggressive B-Zell-Lymphome: Neue Optionen für ältere Patient:innen, Zelltherapien und Monitoring · February 5, 2026 · 18 min
- ASH 2025 – T-Zell-Lymphome: Neue Targets, frühe Rezidive und klinische Konsequenzen · January 19, 2026 · 29 min
- ASH 2025 – Epcoritamab & Co.: Wie sich die Therapie des follikulären Lymphoms verändert · December 19, 2025 · 20 min
- ASH 2025 - AML im Umbruch? · December 17, 2025 · 33 min
- ASH 2025 – Neuigkeiten zur CLL · December 16, 2025 · 24 min
Explore listener stats, chart rankings, contacts and more on the Hämatologie Shortcasts podcast page.